P2-537



Increased ambulatory blood pressure in adolescents with gender dysphoria treated with gonadotropin- releasing hormone analogues D. T. Klink^{1,3}, A. Bokenkamp², E. Atsma¹ and J. Rotteveel^{1,3}

¹Dept. of Pediatrics, Division of Endocrinology, ²Dept. of Pediatrics, Division of Nephrology, ³Center of Expertise on Gender Dysphoria, VU University Medical Center, Amsterdam, The Netherlands

Background

Adolescents with gender dysphoria (GD) are treated with gonadotropin-releasing hormone analogues (GnRHa) to prevent the development

Objective

to prospectively study blood pressure (BP) development during

Methods

- BP was measured using 24 hour
 - ambulatory BP monitoring:
 - prior to start of GnRHa (**D0**)
 - during GnRHa (**D12**)


- of characteristics of the undesired sex.
- Subsequently, sex steroids of the desired sex, cross sex hormones (CSH) are added.
- We reported on the development of hypertension during GnRHa monotherapy¹.

GnRHa treatment in adolescents with GD.

Mean diurnal and nocturnal BP

were converted to SDS according to

- natal sex
- height





Conclusion

- The findings are consistent with previous reports in adult patients that women are more susceptible for BP elevation during GnRHa treatment² than men³.
- This may be due to loss of the protective effect of estrogens
 - in women after menopause BP increases
 - estrogen restored triptorelin induced decreased venous wall distensibility in female rats⁴.
- Clinical implications still need to be assessed
 - CSH in natal girls are androgens which also have BP elevating properties⁴.

• GnRHa therapy can increase nocturnal BP.

D0

D12

D12

D0

- natal girls (transboys) appear to be more at risk.
- clinical relevance (e.g. increased cardiovascular risk) is still unclear.

References

¹Klink et al., Int J Endocrinol Metab, 2015 ²Bonfirraro *et al.*, *Minerva Ginecol*, 1995 ³Levine *et al.*, *Circulation*, 2010 ⁴Varbiro *et al*, *Menopause*, 2002



DOI: 10.3252/pso.eu.54espe.2015



